News & EventsResourcesCareersInvestors
Aptar pharma logo

 

As quality and regulatory expectations continue to rise across the injectable pharmaceutical market, and as therapies, including biologics and GLP-1 medicines, become increasingly complex and valuable, manufacturers are seeking greater confidence in component quality, process robustness, and contamination control.

Premia™ Precision supports greater confidence in component quality and consistency through a clear, impact‑based quality approach - helping manufacturers mitigate risk and meet rising quality expectations for high-value and sensitive injectable therapies.

 

An enhanced quality standard for your high-value injectables

A clear quality approach focused on defining what matters most, preventing quality risks within the process and verifying every component.

Three cards classify safety, functional, and cosmetic quality attributes by level of control

Impact-based quality limits focused on what matters

  • Safety: Zero-defect mindset

  • Function: Strict limits

  • Cosmetic: Controlled limits

Three cards show risk-based quality management, particle targets, and production data

Operational excellence built around risk reduction

  • Risk-based quality management

  • Stringent visible & subvisible particle targets by size

  • Production data supporting performance assessment

Three cards show camera inspection, automated component screening, and final verification

100% vision inspection of every component

  • Advanced camera inspection technology

  • Every component verified

  • Final quality control gate

Define

Premia™ Precision classifies quality attributes according to their potential impact on patient safety, component functionality, and manufacturing performance.

Define Update.png

Prevent

Premia™ Precision integrates a proactive, risk-based approach throughout production, including defined particle targets, aiming for improved quality consistency.

Prevent Update.png

Verify

As a final quality control gate, every Premia™ Precision component undergoes automated vision inspection prior to release.

Verify Update.png

Premia™ Precision: Bringing confidence from start to finish

De-risk development

Support biologics development and commercialization.

Particulate control

Designed to reduce particulate risk at the component level, supporting patient safety.

Lower cost of quality

Can help reduce scrap rates and associated costs.

More control. More consistency. More confidence.

To find out more about how Aptar Pharma can support your project developments, contact our team.